Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Intermittent Sunitinib in Solid Tumors
NCT02058901Phase 1Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2013
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sunitinib in solid tumor (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Maximum Tolerated Dose at 6 weeks and Number of participants with serious and non-serious adverse events at 6 weeks. Started Jul 2013; status: completed.
02
Drugs
sunitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02058901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058901.